LEUKEMIAS

An expert details the treatment options for high-risk myelodysplastic syndrome.

Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.

A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.

Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.

According to David T. Teachey, MD, newly developed therapies have improved remission rates in T-ALL and B-ALL.

Gwen Nichols, MD, reviews the evolving landscape of acute myeloid leukemia for Leukemia Awareness Month.

Asciminib for the treatment of 2 chronic myeloid leukemia subgroups is now under FDA consideration for approval.

Fast track designation has been granted by the FDA to eryaspase for the treatment of patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase.

Asparaginase has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for the treatment of adult and pediatric patients with acute lymphoblastic leukemia.

Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

The FDA has granted approval to Rylaze for use within a chemotherapy regimen to treat adult and pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products that are traditionally used.

Patients with relapsed/refractory acute myeloid leukemia will now be assesses with the off-the-shelf cell therapy CYNK-001 after a case of conversion to minimal residual disease negativity at its highest dose level.

The FDA has granted fast track designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias who harbor a mixed lineage leukemia rearranged or nucleophosmin mutation.

The FDA approved the use of avapritinib for patients with advanced systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

A robust and durable response was seen in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia after receiving a single infusion of KTE-X19, a CAR T-cell therapy.

Early results of a phase 2 study show that the efficacy achieved with the combination of ponatinib and blinatumomab represents a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.

The FDA has accepted the biologic license application (BLA) for ublituximab in combination with umbralisib for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The combination of ibrutinib and venetoclax showed a favorable benefit-risk profile in patients with relapsed or refractory chronic lymphocytic leukemia treated in the VISION/HOVON 141.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed recent data from the study. 

Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.

Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.

Findings suggest that combination regimens may extend overall and progression-free survival.

In an interview with Targeted Oncology, Haris Ali, MD, a hematology oncologist at the City of Hope Cancer Center, discussed the efficacy of ruxolitinib in patients with myelofibrosis, the impact of mutations on ruxolitinib treatment, and the use of the agent in the peri-transplant setting.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

The use of zanubrutinib was found to be noninferior to treatment with ibrutinib for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, meeting the primary end point of the phase 3 ALPINE trial.

The FDA has granted priority review to the sterile injectable therapy SH-111 for the treatment of pediatric patients with T-cell leukemia.

In the phase 1/2 AUGMENT-101 clinical trial, treatment with the novel menin-MLL small molecule inhibitor SNDX-5613 led to robust clinical responses in patients with mixed lineage leukemia rearranged and NPM1c-mutant relapsed or refractory acute leukemias.

In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discusses the chance of cardiovascular toxicities with BTK inhibitors and the safety of acalabrutinib.